Alison Axtman

Alison Axtman

SGC UNC

Axtman

Alison Axtman

(216) 470-7201

Biography

Alison Axtman is a synthetic medicinal chemist with more than 10 years of research experience working at the interface of chemical and biology. Alison earned her PhD in Medicinal Chemistry at the University of Kansas, and carried out her post-doctoral training in the Department of Chemistry at Stanford University. Alison’s research has focused on the synthesis of small molecules that selectively modulate proteins implicated in disease-propagating pathways. As a member of the GSK Chemical Biology department, she led a program to understand the molecular basis of immune modulation by a class of natural products and developed analogs with improved drug properties. Alison is currently a Research Assistant Professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Alison can be most often found at the gym preparing for the next CrossFit or GRID competition with her teammates.

2026

Cellular Context Influences Kinase Inhibitor Selectivity.

Binder MJ, Bashore FM, Dunn Hoffman KK, Damgaard C, Slater M, Drewry DH, Robers MB, Axtman AD

J Med Chem. 2026-2-7 . .doi: 10.1021/acs.jmedchem.5c02916

PMID: 41651452

Development of a Chemical Probe to Enable Characterization of the Casein Kinase 1γ Subfamily.

Capener JL, Kramer TW, Bashore FM, Flory E, Li F, Strang BL, Axtman AD

J Med Chem. 2026-1-26 . .doi: 10.1021/acs.jmedchem.5c02609

PMID: 41587072

Advances in BRET probes for intracellular target engagement studies.

Capener JL, Schwalm MP, Vasta JD, Michaud A, Teske KA, Marsiglia WM, Huber KVM, Dar AC, Knapp S, Axtman AD, Robers MB

Nat Chem Biol. 2026-1-7 . .doi: 10.1038/s41589-025-02103-y

PMID: 41495225

2025

PAK1 inhibitor NVS-PAK1-1 preserves dendritic spines in amyloid/tau exposed neurons and 5xFAD mice.

Yang T, Huhe H, Williams SP, Kaur S, Ay YA, Davis-Gilbert ZW, Cary GA, Paisie C, Butler RR 3rd, Wiley J, Betarbet R, Fu H, Duong D, Seyfried NT, Leal K, Carter GW, Edwards A, Levey AI, Capener JL, Drewry DH, Hossain MA, Oh HJ, Axtman AD, Sukoff Rizzo SJ, Longo FM

Alzheimers Dement. 2025-12-26 . 21(12):e71033 .doi: 10.1002/alz.71033

PMID: 41451871

BRSK2 plays a role in autophagy and cancer cell growth and survival under nutrient deprivation stress via the PIK3C3 pathway.

Maiti A, Axtman AD, Wu R, Redman LJB, Takabe K, Stablewski AB, Yan L, Ciesielski MJ, Zhang J, Evans SS, Kalinski P, Hait NC

Sci Rep. 2025-11-19 . 15(1):40651 .doi: 10.1038/s41598-025-24354-4

PMID: 41258112

Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve.

Min SM, Bashore FM, Smith JL, Havener TM, Howell S, Li H, Couñago RM, Popov KI, Axtman AD

J Med Chem. 2025-1-22 . .doi: 10.1021/acs.jmedchem.4c02531

PMID: 39838960

Drug Development.

Leal K, Axtman AD, Betarbet R, Brennan PE, Carter GW, Fu H, Greenwood AK, Longo FM, Edwards AM, Levey AI, Center ET

Alzheimers Dement. 2025-1-9 . 20 Suppl 6:e089250 .doi: 10.1002/alz.089250

PMID: 39782659

2024

Targeting Na(v)1.7 and Na(v)1.8 with a PIKfyve inhibitor to reverse inflammatory and neuropathic pain.

Rodríguez-Palma EJ, Loya-Lopez S, Min SM, Calderon-Rivera A, Gomez K, Khanna R, Axtman AD

Neurobiol Pain. 2024-12-25 . 17:100174 .doi: 10.1016/j.ynpai.2024.100174

PMID: 39720155

Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2.

Ong HW, Yang X, Smith JL, Taft-Benz S, Howell S, Dickmander RJ, Havener TM, Sanders MK, Brown JW, Couñago RM, Chang E, Krämer A, Moorman NJ, Heise M, Axtman AD, Drewry DH, Willson TM

Molecules. 2024-9-14 . 29(17): .doi: 10.3390/molecules29174158

PMID: 39275006

Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.

Bashore FM, Min SM, Chen X, Howell S, Rinderle CH, Morel G, Silvaroli JA, Wells CI, Bunnell BA, Drewry DH, Pabla NS, Ultanir SK, Bullock AN, Axtman AD

ACS Med Chem Lett. 2024-8-8 . 15(8):1325-1333 .doi: 10.1021/acsmedchemlett.4c00219

PMID: 39140040